MedTrace Logo

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

NCT00333008 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2006-09-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.

Conditions

Interventions

DRUG

Doxil

DRUG

Cyclophosphamide

DRUG

Vincristine

DRUG

Prednisone

DRUG

Rituximab

DRUG

Pegfilgrastim

Sponsors & Collaborators

  • Ortho Biotech Products, L.P.

    collaborator INDUSTRY

  • The Alvin and Lois Lapidus Cancer Institute

    lead OTHER

Principal Investigators

  • Stephen Noga, MD, PhD · Sinai Hospital of Baltimore, The Alvin and Lois Lapidus Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333008 on ClinicalTrials.gov